Marlene Krauss, M.D. v. 180 Life Sciences Corp.

CourtCourt of Chancery of Delaware
DecidedMarch 7, 2022
DocketC.A. No. 2021-0714-LWW
StatusPublished

This text of Marlene Krauss, M.D. v. 180 Life Sciences Corp. (Marlene Krauss, M.D. v. 180 Life Sciences Corp.) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Marlene Krauss, M.D. v. 180 Life Sciences Corp., (Del. Ct. App. 2022).

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

MARLENE KRAUSS, M.D., ) ) Plaintiff, ) ) v. ) C.A. No. 2021-0714-LWW ) 180 LIFE SCIENCES CORP., ) ) Defendant. )

MEMORANDUM OPINION Date Submitted: December 7, 2021 Date Decided: March 7, 2022 Kenneth J. Nachbar, S. Mark Hurd, and Sara Toscano, MORRIS, NICHOLS, ARSHT & TUNNELL LLP, Wilmington, Delaware; Aaron Miner, ARNOLD & PORTER, New York, New York; Counsel for Plaintiff Marlene Krauss, M.D.

Matthew F. Davis, Aaron R. Sims, and Callan R. Jackson, POTTER ANDERSON & CORROON LLP, Wilmington, Delaware; Jeffrey W. Shields, SHIELDS LAW OFFICES, Irvine, California; Counsel for Defendant 180 Life Sciences Corp.

WILL, Vice Chancellor A former director and officer of a Delaware corporation seeks advancement

pursuant to provisions in the company’s charter and bylaws. She is pursuing

advancement of expenses incurred in responding to subpoenas from the Securities

and Exchange Commission, in defending herself against third-party claims in a New

York state action, and in connection with litigation in this court. The company

contests her entitlement to advancement, asserting that she was not made a party to

those proceedings by reason of the fact that she was a fiduciary.

The plaintiff has moved for partial summary judgment on her entitlement to

advancement, including an award of fees-on-fees. This decision grants that motion

in part.

I. FACTUAL BACKGROUND

The following facts are drawn from the undisputed allegations of the Verified

Amended and Supplemental Complaint for Advancement (the “Complaint”) and

from certain documentary exhibits.1

1 Dkt. 7. Citations to “Pl.’s Opening Br. Ex. __” refer to exhibits to the Transmittal Declaration of Sara Toscano in Support of the Opening Brief in Support of Plaintiff’s Motion for Partial Summary Judgment (Dkt. 37). Citations in the form of “Def.’s Answering Br. Ex. __” refer to exhibits to the Transmittal Declaration of Callan R. Jackson in Support of Defendant’s Answering Brief in Opposition to Plaintiff’s Motion for Partial Summary Judgment (Dkt. 39). Page numbers to exhibits are designated by the last three digits of a Bates number, where appropriate.

1 A. Krauss, KBL, and KBL’s Governing Documents

Plaintiff Marlene Krauss is the former Chief Executive Officer and director of

defendant KBL Merger Corp. IV (“KBL”), a special purpose acquisition company.

She served in those roles until her resignation on November 6, 2020—when KBL

entered into a business combination with 180 Life Sciences Corp., Katexco

Pharmaceuticals Corp., and CannBioRx. After the transaction closed, KBL was

renamed 180 Life Sciences Corp. (the “Company”).2

KBL’s original certificate of incorporation provided for advancement of legal

fees incurred by officers and directors in connection with their duties.3 Its July 2017

Amended and Restated Certificate of Incorporation detailed KBL’s advancement

policy in Section 8.2(a):

To the fullest extent permitted by applicable law . . . the Corporation shall indemnify and hold harmless each person who is or was made a party or is threatened to be made a party to or is otherwise involved in any threatened, pending or completed action, suit or proceeding . . . by reason of the fact that he or she is or was a director or officer of the Corporation . . . whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent, or in any other capacity while serving as a director, officer, employee or agent, against all liability and loss suffered and expenses (including, without limitation, attorneys’ fees . . . ) reasonably incurred by such indemnitee in connection with such proceeding. The Corporation shall

2 Verified Am. & Suppl. Compl. for Advancement (“Compl.”) ¶¶ 2-3 (Dkt. 7). 3 Id. ¶ 6.

2 to the fullest extent not prohibited by applicable law pay the expenses (including attorneys’ fees) incurred by an indemnitee in defending or otherwise participating in any proceeding in advance of its final disposition . . . .4

Section 8.2(a) also provided that approval by KBL’s board of directors (the “Board”)

was required for advancement of proceedings “initiated” by officers and directors:

Notwithstanding the foregoing provisions of this Section 8.2(a), except for proceedings to enforce rights to indemnification and advancement of expenses, the Corporation shall indemnify and advance expenses to an indemnitee in connection with a proceeding (or part thereof) initiated by such indemnitee only if such proceeding (or part thereof) was authorized by the Board.5 And Section 8.2(b) contained a non-exclusivity provision:

The rights to indemnification and advancement of expenses conferred on any indemnitee . . . shall not be exclusive of any other rights that any indemnitee may have or hereafter acquire under law, this Amended and Restated Certificate, the Bylaws, an agreement, vote of stockholders or disinterred directors, or otherwise.6 Section 8.2 remains unchanged in KBL’s Second Amended and Restated Certificate

of Incorporation (the “Charter”), which it adopted in connection with the business

combination.7

4 Pl.’s Opening Br. Ex. B § 8.2(a). 5 Id. 6 Id. § 8.2(b). 7 Pl.’s Opening Br. Ex. C (“Charter”) § 8.2; Compl. ¶ 7.

3 The Company’s Amended and Restated Bylaws (the “Bylaws”) also provide

for an advancement right in Section 8.2:

[A]n Indemnitee shall also have the right to be paid by the Corporation to the fullest extent not prohibited by applicable law the expenses (including, without limitation, attorneys’ fees) incurred in defending or otherwise participating in any such proceeding in advance of its final disposition . . . provided, however, that, if the DGCL requires, an advancement of expenses incurred by an Indemnitee . . . shall be made only upon the Corporation’s receipt of an undertaking . . . .8

Unlike the advancement right established in the Charter, the Bylaws do not require

Board approval for advancement of expenses related to certain types of proceedings.

B. The Lawsuits and Investigation

After the business combination closed, the United States Securities and

Exchange Commission launched an investigation into KBL’s business combination.

In April 2021, the SEC served Krauss with four subpoenas in connection with its

investigation.9 One subpoena directed Krauss to personally produce documents (the

“Krauss Subpoena”).10 The other three subpoenas were directed to entities affiliated

with Krauss that were involved in the business combination: KBL IV Sponsor LLC

8 Pl.’s Opening Br. Ex. D (“Bylaws”) § 8.2(a). 9 Compl. ¶¶ 1, 10; see Pl.’s Opening Br. Ex. E. 10 Compare Pl.’s Opening Br. Ex. E at 080 (“The subpoena requires you to provide us with documents.”), to, e.g., id. at 056 (“The subpoena requires KBL Sponsor to produce documents to the SEC.”).

4 (“KBL Sponsor”), KBL Healthcare Ventures LP, and KBL Healthcare Management,

Inc (together, the “KBL Entities”).11 Krauss was served with a follow-up subpoena

to the Krauss Subpoena in May 2021.12

In April 2021, the Company initiated litigation against Tyche Capital, LLC in

New York state court (the “Tyche Action”), alleging breach of contract.13 In May

2021, Tyche asserted third-party claims and served Krauss with a third-party

summons.14

On September 1, 2021, the Company filed a complaint against Krauss, KBL

Sponsor, and KBL Healthcare Management, Inc. in this court (the “Direct

Action”).15 The Company is pressing claims including breach of fiduciary duty and

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Brown v. LiveOps, Inc.
903 A.2d 324 (Court of Chancery of Delaware, 2006)
Stifel Financial Corp. v. Cochran
809 A.2d 555 (Supreme Court of Delaware, 2002)
Hibbert v. Hollywood Park, Inc.
457 A.2d 339 (Supreme Court of Delaware, 1983)
Senior Tour Players v. GOLFTOWN
853 A.2d 124 (Court of Chancery of Delaware, 2004)
Paolino v. MacE Security International, Inc.
985 A.2d 392 (Court of Chancery of Delaware, 2009)
Citrin v. International Airport Centers LLC
922 A.2d 1164 (Court of Chancery of Delaware, 2006)
Homestore, Inc. v. Tafeen
888 A.2d 204 (Supreme Court of Delaware, 2005)
Fasciana v. Electronic Data Systems Corp.
829 A.2d 160 (Court of Chancery of Delaware, 2003)
Citadel Holding Corp. v. Roven
603 A.2d 818 (Supreme Court of Delaware, 1992)
Hill International, Inc. v. Opportunity Partners L.P.
119 A.3d 30 (Supreme Court of Delaware, 2015)
Danenberg v. Fitracks, Inc.
58 A.3d 991 (Court of Chancery of Delaware, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Marlene Krauss, M.D. v. 180 Life Sciences Corp., Counsel Stack Legal Research, https://law.counselstack.com/opinion/marlene-krauss-md-v-180-life-sciences-corp-delch-2022.